Logo image of RNTX

REIN THERAPEUTICS INC (RNTX) Stock Fundamental Analysis

NASDAQ:RNTX - US00887A2042 - Common Stock

1.35 USD
-0.04 (-2.88%)
Last: 9/2/2025, 8:00:02 PM
1.4 USD
+0.05 (+3.7%)
After Hours: 9/2/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, RNTX scores 2 out of 10 in our fundamental rating. RNTX was compared to 542 industry peers in the Biotechnology industry. RNTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RNTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNTX has reported negative net income.
In the past year RNTX has reported a negative cash flow from operations.
RNTX had negative earnings in each of the past 5 years.
RNTX had a negative operating cash flow in each of the past 5 years.
RNTX Yearly Net Income VS EBIT VS OCF VS FCFRNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -102.91%, RNTX is not doing good in the industry: 76.75% of the companies in the same industry are doing better.
The Return On Equity of RNTX (-123.20%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -102.91%
ROE -123.2%
ROIC N/A
ROA(3y)-80.04%
ROA(5y)-84.72%
ROE(3y)-92.8%
ROE(5y)-102.4%
ROIC(3y)N/A
ROIC(5y)N/A
RNTX Yearly ROA, ROE, ROICRNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

RNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNTX Yearly Profit, Operating, Gross MarginsRNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for RNTX has been increased compared to 1 year ago.
The number of shares outstanding for RNTX has been increased compared to 5 years ago.
There is no outstanding debt for RNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNTX Yearly Shares OutstandingRNTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RNTX Yearly Total Debt VS Total AssetsRNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RNTX has an Altman-Z score of -8.29. This is a bad value and indicates that RNTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.29, RNTX is not doing good in the industry: 68.63% of the companies in the same industry are doing better.
RNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.29
ROIC/WACCN/A
WACCN/A
RNTX Yearly LT Debt VS Equity VS FCFRNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

RNTX has a Current Ratio of 0.86. This is a bad value and indicates that RNTX is not financially healthy enough and could expect problems in meeting its short term obligations.
RNTX has a Current ratio of 0.86. This is amonst the worse of the industry: RNTX underperforms 89.30% of its industry peers.
RNTX has a Quick Ratio of 0.86. This is a bad value and indicates that RNTX is not financially healthy enough and could expect problems in meeting its short term obligations.
RNTX's Quick ratio of 0.86 is on the low side compared to the rest of the industry. RNTX is outperformed by 88.93% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.86
RNTX Yearly Current Assets VS Current LiabilitesRNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

RNTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.01%, which is quite good.
EPS 1Y (TTM)17.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNTX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.17%
EPS Next 2Y36.17%
EPS Next 3Y22.85%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNTX Yearly EPS VS EstimatesRNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNTX Price Earnings VS Forward Price EarningsRNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNTX Per share dataRNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RNTX's earnings are expected to grow with 22.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.17%
EPS Next 3Y22.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REIN THERAPEUTICS INC

NASDAQ:RNTX (9/2/2025, 8:00:02 PM)

After market: 1.4 +0.05 (+3.7%)

1.35

-0.04 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners24.57%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap31.47M
Analysts82.86
Price Target7.14 (428.89%)
Short Float %0.11%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.41%
Min EPS beat(2)-24.78%
Max EPS beat(2)-0.04%
EPS beat(4)1
Avg EPS beat(4)-360.27%
Min EPS beat(4)-1451.7%
Max EPS beat(4)35.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-30%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-16.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS2.06
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -102.91%
ROE -123.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.04%
ROA(5y)-84.72%
ROE(3y)-92.8%
ROE(5y)-102.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.86
Altman-Z -8.29
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
EPS Next Y75.17%
EPS Next 2Y36.17%
EPS Next 3Y22.85%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.77%
OCF growth 3YN/A
OCF growth 5YN/A